By Mill Chart
Last update: Dec 13, 2023
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if DEXCOM INC (NASDAQ:DXCM) is suited for growth investing. Investors should of course do their own research, but we spotted DEXCOM INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
As part of its analysis, ChartMill provides a comprehensive Fundamental Rating for each stock. This rating, ranging from 0 to 10, is updated on a daily basis and is based on the evaluation of various fundamental indicators and properties.
We assign a fundamental rating of 7 out of 10 to DXCM. DXCM was compared to 202 industry peers in the Health Care Equipment & Supplies industry. While DXCM has a great profitability rating, there are some minor concerns on its financial health. DXCM is growing strongly while it is still valued neutral. This is a good combination! These ratings could make DXCM a good candidate for growth investing.
For an up to date full fundamental analysis you can check the fundamental report of DXCM
More growth stocks can be found in our Lois Navellier screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
DEXCOM INC
NASDAQ:DXCM (4/19/2024, 7:00:00 PM)
After market: 129.32 -1.39 (-1.06%)130.71
-3.59 (-2.67%)
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
This April, discover three game-changing tech stocks with disruptive technologies poised to future-proof your portfolio in 2024.
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout.
DoorDash, DexCom, and Advanced Micro Devices are three Nasdaq stocks to sell before reality sets in as exuberance may be fading.
Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments
The Relative Strength (RS) Rating for DexCom stock entered a new percentile Monday, with a rise from 80 to 83.
These healthcare companies' target markets substantially overlap.